Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial
PaperCitations, authors & open-access status
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 153 citations, 2021 year and closed oa status.
153
Citations
2021
Year
closed
OA Status